Nature Reviews Drug Discovery contents February 2016 Volume 15 Number 2 pp 71-143

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
February 2016 Volume 15 Number 2		Advertisement
Impact Factor 41.908 *	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Correspondence Also this month  Featured article: Optogenetics enlightens neuroscience drug discovery Chenchen Song & Thomas Knöpfel	Open for Submissions Online-only and open access, npj Primary Care Respiratory Medicine is the only fully-indexed scientific journal devoted to the management of respiratory diseases in primary care. The journal has an Impact Factor of 2.504. Explore the benefits of submitting your next research article.
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Comment: Moving from 'diagnose and treat' to 'predict and pre-empt' in neuropsychiatric disorders Vaibhav A. Narayan & Husseini K. Manji p71 | doi:10.1038/nrd.2015.20 What could be the benefits of moving the treatment paradigm for serious neuropsychiatric disorders towards earlier intervention, and what is needed to achieve this? Abstract | Full Text | PDF
NEWS AND ANALYSIS		Top
2015 FDA drug approvals Asher Mullard p73 | doi:10.1038/nrd.2016.15 FDA approval rate continues to surge, with 45 green lights for new drugs granted in 2015. PDF
NEWS IN BRIEF EMA recommended 39 new drug approvals last year Asher Mullard p77 | doi:10.1038/nrd.2016.16 PDF
Pfizer expands hunt for immuno-oncology biomarkers Asher Mullard p77 | doi:10.1038/nrd.2016.17 PDF
Fragile X drug development flounders Asher Mullard p77 | doi:10.1038/nrd.2016.18 PDF
BIOBUSINESS BRIEFS Deal watch: Biopharma deal-making in 2015: changing the pharma landscape Amanda Micklus & Steven Muntner p78 | doi:10.1038/nrd.2016.10 PDF
AN AUDIENCE WITH Michael Hanson p80 | doi:10.1038/nrd.2016.12 Michael Hanson, president of the GPCR Consortium, discusses how industry and academic partners are shedding light on one of the most important classes of drug targets. PDF
FROM THE ANALYST'S COUCH Combination therapies in oncology Rachel M. Webster p81 | doi:10.1038/nrd.2016.3 This analysis presents anticancer drug combinations that contain two or more targeted agents and discusses their impact on oncology markets. PDF
RESEARCH HIGHLIGHTS Top Huntington disease: Boosting PPARδ blocks neurodegeneration p83 | doi:10.1038/nrd.2016.1 PDF Drug delivery: New targets for drug delivery across the BBB p84 | doi:10.1038/nrd.2016.14 PDF Screening: A platform for probing protein-aggregation inhibitors p84 | doi:10.1038/nrd.2016.8 PDF Cancer: Mutant p53 rescued by aggregation inhibitor p85 | doi:10.1038/nrd.2016.13 PDF Target identification: Putting the brakes on preterm labour p86 | doi:10.1038/nrd.2016.11 PDF IN BRIEF Metabolic disease: Targeting aP2 reverses diabetes | Drug discovery: Optimizing phenotypic screens | Kidney disease: AIM promotes recovery from AKI | Respiratory diseases: Lung airway-on-a-chip PDF Drug Discovery JOBS of the week Post-Doctoral Research Fellow - Peptide Drug Discovery Fred Hutchinson Cancer Research Center Postdoctoral Fellow The University of Tennessee Health Science Center Post-doctoral Research Scientist Inserm More Science jobs from Drug Discovery EVENT Drug Discovery Chemistry 19.04.16 San Diego, USA More science events from
Advertisement
npj Vaccines is an online-only, open access, multidisciplinary journal dedicated to publishing cutting-edge research and development on human and veterinary vaccines. npj Vaccines is now open for submissions — explore the benefits of submitting your next manuscript to the journal.
PERSPECTIVES		Top
OPINION The drug-target residence time model: a 10-year retrospective Robert A. Copeland p87 | doi:10.1038/nrd.2015.18 Over the past decade, the drug-target residence time model has been broadly applied to drug discovery programmes across multiple therapeutic areas. To mark the 10 year anniversary of this model, Copeland discusses the benefits of assessing residence time, highlighting some of the advances in its theory and application. Abstract | Full Text | PDF
REVIEWS		Top
Optogenetics enlightens neuroscience drug discovery Chenchen Song & Thomas Knöpfel p97 | doi:10.1038/nrd.2015.15 Optogenetics has already had a major impact on neuroscience research, particularly in the study of cognitive and emotional processes. Here, Song and Knopfel discuss emerging applications of optogenetic technologies, focusing on their potential to transform neuroscience drug discovery programmes and to provide novel therapeutic approaches for conditions such as Parkinson disease, mood disorders and epilepsy. Abstract | Full Text | PDF
Central nervous system myeloid cells as drug targets: current status and translational challenges Knut Biber, Thomas Möller, Erik Boddeke & Marco Prinz p110 | doi:10.1038/nrd.2015.14 CNS myeloid cells mediate the local immune response during development, health and brain diseases and are emerging as potential therapeutic targets for the treatment of neurological and psychiatric disorders. Here, Biber and colleagues assess strategies for targeting CNS myeloid cells and consider key issues associated with their clinical translation. Abstract | Full Text | PDF
Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis Johan Kreuger & Mia Phillipson p125 | doi:10.1038/nrd.2015.2 Cells within the microvascular compartment, particularly leukocytes, can affect angiogenesis, inflammation and fibrosis. Kreuger and Phillipson discuss how to target these cells therapeutically, focusing on ways to interfere with intracellular communication and reprogramme leukocytes, which could have applications in the design of drugs and their delivery systems. Abstract | Full Text | PDF
Corrigendum: Oncolytic viruses: a new class of immunotherapy drugs Howard L. Kaufman, Frederick J. Kohlhapp & Andrew Zloza p143 | doi:10.1038/nrd.2015.23 Full Text | PDF
Erratum: Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void? David Brown p143 | doi:10.1038/nrd.2016.9 Full Text | PDF
CORRESPONDENCE		Top
Correspondence: Implications of endogenous roles of transporters for drug discovery: hitchhiking and metabolite-likeness Douglas B. Kell p143 | doi:10.1038/nrd.2015.44 Full Text | PDF
Advertisement
npj Vaccines is an online-only, open access, multidisciplinary journal dedicated to publishing cutting-edge research and development on human and veterinary vaccines. npj Vaccines is now open for submissions — explore the benefits of submitting your next manuscript to the journal.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2013 Journal Citation Report (Thomson Reuters, 2014)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.